<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00688636</url>
  </required_header>
  <id_info>
    <org_study_id>C0168X75</org_study_id>
    <nct_id>NCT00688636</nct_id>
  </id_info>
  <brief_title>Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery</brief_title>
  <official_title>Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centocor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, placebo-controlled pilot study to determine endoscopic recurrence of Crohn's
      disease 12 months after curative, resective ileal or ileocolonic surgery in patients
      receiving post-operative infliximab or placebo
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endoscopic Recurrence: the Proportion of Patients in Endoscopic Recurrence at One Year</measure>
    <time_frame>one year</time_frame>
    <description>Endoscopic recurrence was defined as i2,i3,i4. We used the Rutgeerts' Endoscopic Scoring System. Scores as follows i0, no lesions; i1, 5 or fewer aphthous lesions; i2, more than 5 aphthous lesions with normal mucosa between the lesions or skip areas of larger lesions or lesions confined to the ileocolonic anastomosis; i3, diffuse, aphthous ileitis with diffusely inflamed mucosa; and i4, diffuse inflammation with large ulcers, nodules, and/or narrowing. Endoscopic recurrence was defined as i2,i3,i4 and endoscopic remission was defined as i0 or i1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Recurrence at One Year: Defined by Crohn's Disease Activity Index (CDAI) &gt; 200</measure>
    <time_frame>One year</time_frame>
    <description>The Crohn's Disease Activity Index (CDAI) is calculated by a measurement of symptoms, signs, and lab tests over a time period of the previous 7 days. The CDAI includes: Number of very soft stools; sum of abdominal pain ratings: (0=none, 1= mild, 2=moderate, 3=severe); general well being (0=well, 1=slightly below par, 2=poor, 3=very poor, 4=terrible); Symptoms or findings presumed related to Crohn's disease (present): arthritis or arthralgia, iritis or uveitis, erythema nodosum, pyoderma gangrenosum, aphthous stomatitis, anal fissure, fistula or perirectal abscess, other bowel related fistula, febrile episode over 100 degrees during past week, taking lomotil or opiates for diarrhea, abnormal mass (0=none; 0.4=questionable; 1=present) hematocrit [(typical-current) X 6] Normal average male = 47, female =42, body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological Recurrence of Crohn's Disease as Determined From Biopsies of Neo-terminal Ileum Above the Ileocolonic Anastomosis</measure>
    <time_frame>One year</time_frame>
    <description>Histologic recurrence based on a histologic activity score and the presence of polymononuclear cells. The maximum score is 14 per biopsy site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive Protein Concentration as a Surrogate Marker of Inflammation</measure>
    <time_frame>one year</time_frame>
    <description>The CRP was obtained at each study visit as a surrogate marker of inflammation. The CRP was recorded as milligram per deciliter (mg/dl). A normal CRP was 0-0.8 mg/dl; levels exceeding 0.8 mg/dl indicated inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Erythrocyte Sedimentation Rate</measure>
    <time_frame>one year</time_frame>
    <description>erythrocyte sedimentation rate value - blood test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>infliximab</intervention_name>
    <description>5 mg/kg IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Remicade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men/women &gt; 18 years of age

          -  curative resection/ileocolonic anastomosis for Crohn's disease

          -  may have received previously received infliximab

          -  if on oral aminosalicylates or corticosteroids, dose must be stable for 4 weeks prior
             to surgery

          -  if on 6-mercaptopurine,azathioprine or methotrexate,individual must have been on it
             for minimum of 3 months prior to surgery with stable dose for 4 weeks

          -  men and women must use adequate birth control for duration of study and for 6 months
             after receiving the last infusion

          -  antibiotics for treatment of Crohn's disease must be discontinued within 12 weeks
             after surgery; antibiotics are allowable throughout study as long as primary purpose
             of antibiotic therapy is not for primary treatment of Crohn's disease

          -  screening lab results must meet screening criteria (hemoglobin = or &gt; 8.5g/dL; Serum
             glutamic oxaloacetic transaminase ,3 times upper normal limit,platelets =or&gt; 100 x 10
             9th/L; lymphocytes count =or&gt; 0.5 x 10 9th/L and neutrophils =or&gt; 1.0 x 10 9th/L

          -  have a documented negative reaction to a purified protein derivative skin test
             performed within 3 months prior to baseline

          -  have a normal chest radiograph results within 3 months prior to baseline

          -  are capable of providing written informed consent and obtained prior to conducting any
             protocol-specified procedures

          -  willing to adhere to the study visit schedule and other protocol requirements

          -  are considered eligible according to the tuberculosis eligibility assessment,
             screening and early detection of reactivation rules

          -  patients who undergo resective surgery and primary ileocolonic anastomosis with a
             temporary ileostomy upon takedown of the diverting ileostomy.

        Exclusion Criteria:

          -  patients with greater than 10 years of Crohn's disease requiring first resection of a
             short (&lt;10cm) fibrostenotic stricture

          -  macroscopically active disease at anastomosis at time of surgery

          -  presence of stoma

          -  prior severe infusion reaction to infliximab

          -  history of anaphylaxis to murine products or other chimeric proteins

          -  any of the following medications taken within 12 weeks of surgery: cyclosporine,
             tacrolimus, sirolimus, mycophenolate mofetil, investigational drugs, or medications
             targeted at reducing tumor necrosis factor

          -  have a positive stool culture for enteric pathogens, pathogenic ova or parasites, or
             Clostridium difficile toxin and have clinically significant signs of an enteric
             infection at screening

          -  women who are pregnant, nursing or planning pregnancy during the trial or within 6
             months after the last infusion

          -  patient with active tuberculosis, patient newly diagnosed with latent tuberculosis
             who's receiving tuberculosis prophylaxis, patient with recent close contact to
             individual with active tuberculosis

          -  have or have had opportunistic infection within 6 months of screening

          -  have chest radiograph within 3 months prior to screening that shows malignancy,
             infection, or abnormalities suggestive of tuberculosis

          -  documentation of seropositive for HIV

          -  documentation of a positive test for hepatitis B surface antigen or a history of
             documented hepatitis C

          -  have current signs/symptoms of systemic lupus erythematosus, or severe progressive, or
             uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary,
             cardiac, neurologic or cerebral diseases

          -  presence of a transplanted solid organ (with exception of corneal transplant &gt; 3
             months prior to randomization)

          -  Have any current or known malignancy or have history of malignancy within 5 years of
             screening(except for squamous or basal cell carcinoma of the skin that has been fully
             excised with no evidence of recurrence)

          -  have history of lymphoproliferative disease or splenomegaly

          -  have known substance abuse(drug/alcohol)/dependency within the previous 3 years,
             history of noncompliance with medical regimens, or other condition that may interfere
             with adherence to protocol requirements

          -  are unwilling/unable to undergo multiple venipunctures because of poor tolerability or
             lack of easy access

          -  known history of demyelinating disease

          -  a chronic or recurrent infectious disease

          -  serious infection, hospitalization for infection, or treatment with IV antibiotics for
             infection within 2 months prior to randomization

          -  a serious concomitant illness that may interfere with participation in trial

          -  concomitant diagnosis/history of congestive heart failure

          -  current use of prescription doses or chronic/frequent use of non-steroidal
             anti-inflammatory drugs

          -  ulcerative colitis

          -  concurrent participation in another investigative trial

          -  use of any investigational drug within 30 days prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel D Regueiro, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, Harrison J, Plevy SE. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology. 2009 Feb;136(2):441-50.e1; quiz 716. doi: 10.1053/j.gastro.2008.10.051. Epub 2008 Oct 31.</citation>
    <PMID>19109962</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2008</study_first_submitted>
  <study_first_submitted_qc>June 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <results_first_submitted>April 1, 2016</results_first_submitted>
  <results_first_submitted_qc>September 9, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 26, 2016</results_first_posted>
  <last_update_submitted>September 9, 2016</last_update_submitted>
  <last_update_submitted_qc>September 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Miguel Regueiro</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between 2005 and 2007 there were 24 adult patients with ileal or ileocolonic Crohn's disease undergoing resection who participated in the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Infliximab</title>
          <description>infliximab: 5 mg/kg IV at baseline, 2 weeks, 6 weeks and then every 8 weeks for 54 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo: placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks for 54 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Infliximab</title>
          <description>infliximab: 5 mg/kg IV at baseline, 2 weeks, 6 weeks and then every 8 weeks for 54 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo: placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks for 54 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.0" lower_limit="28" upper_limit="49"/>
                    <measurement group_id="B2" value="32.0" lower_limit="26" upper_limit="45"/>
                    <measurement group_id="B3" value="38.0" lower_limit="27.0" upper_limit="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Endoscopic Recurrence: the Proportion of Patients in Endoscopic Recurrence at One Year</title>
        <description>Endoscopic recurrence was defined as i2,i3,i4. We used the Rutgeerts’ Endoscopic Scoring System. Scores as follows i0, no lesions; i1, 5 or fewer aphthous lesions; i2, more than 5 aphthous lesions with normal mucosa between the lesions or skip areas of larger lesions or lesions confined to the ileocolonic anastomosis; i3, diffuse, aphthous ileitis with diffusely inflamed mucosa; and i4, diffuse inflammation with large ulcers, nodules, and/or narrowing. Endoscopic recurrence was defined as i2,i3,i4 and endoscopic remission was defined as i0 or i1.</description>
        <time_frame>one year</time_frame>
        <population>The proportion of patients with endoscopic recurrence (&gt; or = i2) at 1 year after surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Infliximab</title>
            <description>infliximab: 5 mg/kg IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6</description>
          </group>
        </group_list>
        <measure>
          <title>Endoscopic Recurrence: the Proportion of Patients in Endoscopic Recurrence at One Year</title>
          <description>Endoscopic recurrence was defined as i2,i3,i4. We used the Rutgeerts’ Endoscopic Scoring System. Scores as follows i0, no lesions; i1, 5 or fewer aphthous lesions; i2, more than 5 aphthous lesions with normal mucosa between the lesions or skip areas of larger lesions or lesions confined to the ileocolonic anastomosis; i3, diffuse, aphthous ileitis with diffusely inflamed mucosa; and i4, diffuse inflammation with large ulcers, nodules, and/or narrowing. Endoscopic recurrence was defined as i2,i3,i4 and endoscopic remission was defined as i0 or i1.</description>
          <population>The proportion of patients with endoscopic recurrence (&gt; or = i2) at 1 year after surgery</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0005</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Recurrence at One Year: Defined by Crohn's Disease Activity Index (CDAI) &gt; 200</title>
        <description>The Crohn's Disease Activity Index (CDAI) is calculated by a measurement of symptoms, signs, and lab tests over a time period of the previous 7 days. The CDAI includes: Number of very soft stools; sum of abdominal pain ratings: (0=none, 1= mild, 2=moderate, 3=severe); general well being (0=well, 1=slightly below par, 2=poor, 3=very poor, 4=terrible); Symptoms or findings presumed related to Crohn's disease (present): arthritis or arthralgia, iritis or uveitis, erythema nodosum, pyoderma gangrenosum, aphthous stomatitis, anal fissure, fistula or perirectal abscess, other bowel related fistula, febrile episode over 100 degrees during past week, taking lomotil or opiates for diarrhea, abnormal mass (0=none; 0.4=questionable; 1=present) hematocrit [(typical-current) X 6] Normal average male = 47, female =42, body weight</description>
        <time_frame>One year</time_frame>
        <population>CDAI score &gt; 200</population>
        <group_list>
          <group group_id="O1">
            <title>Infliximab</title>
            <description>infliximab: 5 mg/kg IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Recurrence at One Year: Defined by Crohn's Disease Activity Index (CDAI) &gt; 200</title>
          <description>The Crohn's Disease Activity Index (CDAI) is calculated by a measurement of symptoms, signs, and lab tests over a time period of the previous 7 days. The CDAI includes: Number of very soft stools; sum of abdominal pain ratings: (0=none, 1= mild, 2=moderate, 3=severe); general well being (0=well, 1=slightly below par, 2=poor, 3=very poor, 4=terrible); Symptoms or findings presumed related to Crohn's disease (present): arthritis or arthralgia, iritis or uveitis, erythema nodosum, pyoderma gangrenosum, aphthous stomatitis, anal fissure, fistula or perirectal abscess, other bowel related fistula, febrile episode over 100 degrees during past week, taking lomotil or opiates for diarrhea, abnormal mass (0=none; 0.4=questionable; 1=present) hematocrit [(typical-current) X 6] Normal average male = 47, female =42, body weight</description>
          <population>CDAI score &gt; 200</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Histological Recurrence of Crohn's Disease as Determined From Biopsies of Neo-terminal Ileum Above the Ileocolonic Anastomosis</title>
        <description>Histologic recurrence based on a histologic activity score and the presence of polymononuclear cells. The maximum score is 14 per biopsy site.</description>
        <time_frame>One year</time_frame>
        <population>Histologic activity score</population>
        <group_list>
          <group group_id="O1">
            <title>Infliximab</title>
            <description>infliximab: 5 mg/kg IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6</description>
          </group>
        </group_list>
        <measure>
          <title>Histological Recurrence of Crohn's Disease as Determined From Biopsies of Neo-terminal Ileum Above the Ileocolonic Anastomosis</title>
          <description>Histologic recurrence based on a histologic activity score and the presence of polymononuclear cells. The maximum score is 14 per biopsy site.</description>
          <population>Histologic activity score</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-reactive Protein Concentration as a Surrogate Marker of Inflammation</title>
        <description>The CRP was obtained at each study visit as a surrogate marker of inflammation. The CRP was recorded as milligram per deciliter (mg/dl). A normal CRP was 0-0.8 mg/dl; levels exceeding 0.8 mg/dl indicated inflammation.</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infliximab</title>
            <description>infliximab: 5 mg/kg IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6</description>
          </group>
        </group_list>
        <measure>
          <title>C-reactive Protein Concentration as a Surrogate Marker of Inflammation</title>
          <description>The CRP was obtained at each study visit as a surrogate marker of inflammation. The CRP was recorded as milligram per deciliter (mg/dl). A normal CRP was 0-0.8 mg/dl; levels exceeding 0.8 mg/dl indicated inflammation.</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.05" upper_limit="0.8"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.2" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Erythrocyte Sedimentation Rate</title>
        <description>erythrocyte sedimentation rate value - blood test</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infliximab</title>
            <description>infliximab: 5 mg/kg IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Erythrocyte Sedimentation Rate</title>
          <description>erythrocyte sedimentation rate value - blood test</description>
          <units>mm/h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="10" upper_limit="40"/>
                    <measurement group_id="O2" value="19" lower_limit="9" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Infliximab</title>
          <description>infliximab: 5 mg/kg IV at baseline, 2 weeks, 6 weeks and then every 8 weeks for 54 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo: placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks for 54 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>partial small-bowel obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>crohn's disease exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>lupus-like reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Infusion reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>pyleonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>abcess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lung nodules</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations to our study included a small sample size, a disproportionate number of smokers in the infliximab group, more patients on immunomodulators in the placebo group, and inclusion of patients who had previously received infliximab.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Research Coordinator</name_or_title>
      <organization>Univerisity of Pittsburgh</organization>
      <phone>412-648-9173</phone>
      <email>goldbyreffnerka@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

